 |
Guidepoint Surveys 100 Physicians in Europe and US To Evaluate Impact of News Linking Cancer to Leading Diabetes Therapy |
News
The European Association for the Study of Diabetes announced that, according to the data published in the journal Diabetologia, there may be a possible link between the use of Sanofi-Aventis’ Lantus (insulin glargine) and an increased risk of cancer
Client Need
Since Lantus is a very popular insulin product generating major revenue sources for Sanofi-Aventis, our Client sought to gauge the impact of this news on the potential use of Lantus and other competing products by primary care physicians and endocrinologists across the US and Europe
the solution
Guidepoint helped the Client draft a quick survey instrument that could be targeted to these physician groups in both the US and Europe. Guidepoint was able to obtain 100 completed survey responses and the Client was able to use the data to test their hypothesis on both near term and long term impact of this news.
